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ABSTRACT	 	Activating	the	immune	system	to	eliminate	cancer	cells	and	produce	clinically	relevant	response	has	been	a	long	 standing	 goal	 of	 cancer	 research.	 Most	 promising	 therapeutic	 approaches	 of	 activating	 antitumor	immunity	 include	 immune	 checkpoint	 inhibitors.	 Our	 immune	 system	 protect	 us	 from	 disease,	 killing	bacteria	and	virus.	One	main	type	of	immune	cell	called	T-cells.	T-cells	have	protein	that	turn	it	off.	These	are	called	checkpoint.	 Immune	checkpoint	are	accessory	molecules	 that	either	promote	or	 inhibit	T-cell	activation.	Checkpoint	inhibitor	are	a	type	of	immunotherapy.	They	block	protein	that	stops	the	immune	system	from	attacking	the	cancer	cells.	Checkpoint	inhibitor	are	a	type	of	monoclonal	antibody	or	targeted	treatment.	Immune	system	cells,	such	as	T-cells	and	Antigen	presenting	cells	(APCs),	defend	and	protect	the	body.	Immune	system	play	an	important	role	in	controlling	and	eradicating	cancer.	Cytotoxic	T	lymphocytes	associated	protein	4(CTLA-4)	and	Programmed	cell	dealth	protein	(PD-1)	are	checkpoint	protein	which	is	the	negative	regulation	of	T-cell	immune	function.	Inhibition	of	the	target,	results	in	increased	activation	of	immune	system.	
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INTRODUCTION	Our	immune	system	protect	us	from	disease,	killing	bacteria	 and	 virus.	 One	 main	 type	 of	 immune	 cell	called	 T-cells.	 T-cells	 have	 protein	 that	 turn	 it	 off.	These	 are	 called	 checkpoint.	 Some	 checkpoint	protein	 help	 T-cells	 to	 become	 active,	 for	 example	when	an	infection	is	present.	But	the	T-cells	are	active	
for	too	long	they	should	really	be	attacking	the	cancer	cells.	 So	 the	 cancer	 cells	 are	 pushing	 to	 stop	 	 the	immune	 system	 and	T-cell	 can	 no	 longer	 recognize	and	 kill	 cancer	 cells.	 Drugs	 that	 block	 checkpoint	protein	 are	 called	 checkpoint	 inhibitors.	 They	 stop	the	protein	on	the	cancer	cells	from	pushing	the	stop	button.	This	turns	the	immune	system	back	on	and	T-cells	 are	 able	 to	 find	 and	 attack	 the	 cancer	 cells.	Nivolumab	are	checkpoint	inhibitors.	Ipilimumab	is	a	monoclonalantibody	that	attach	to	CTLA-4	and	stop	it	from	 working.	 This	 can	 boost	 the	 body’s	 immune	response	 against	 cancer	 cells.	 Unlike	 radio	 and	chemotherapy	which	 aim	 to	 directly	 interfere	with	tumor	 cell	 growth	 and	 survival,	 Immunotherapy	target	 the	 tumour	 indirectly	 by	 boosting	 the	antitumor	 immune	 response	 that	 spontaneously	arise	in	many	patients[1].	
Fundamental	mechanism	of	 immune	checkpoint	
blockade	therapy	Immune	 checkpoint	 blockade	 removes	 inhibitory	signals	 of	 T-cell	 activation,	 which	 enables	 tumour-reactive	T	 cells	 to	 overcome	 regulatory	mechanism	and	form	an	effective	antitumor	response.	 	 Immune	checkpoint	 blockade	 therapies	 are	 now	 FDA	approved	for	the	treatment	of	a	broad	range	of	tumor	type	with	approval	likely	for	additional	indications	in	
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the	 future.	 Since	 the	 2011	 FDA	 approval	 of	ipilimumab	 (anti-CTLA4)	 for	 the	 treatment	 of	metastatic	 melanoma,	 5	 additional	 checkpoint	blockade	therapies,	all	targeting	the	PD-1/PD-L1	axis,	have	 been	 approved	 for	 the	 treatment	 of	 a	 broad	range	of	 tumor	types.	Additionally,	 ipilimumab	plus	nivolumab	(anti-PD-1)	combination	therapy	has	been	approved	 for	 the	 treatment	of	advanced	melanoma.	The	 mechanism	 of	 checkpoint	 blockade	 is	 to	 be	understood[2].	Five	types	of	mechanism	involved	are;	1. Mechanisms	of	CTLA4-mediated	negative	 cost-imulation.	2. Mechanism	of	PD-1-mediated	attenuation	of	T-cell	activity.	3. Mechanism	 of	 negative	 costimulation	 versus	mechanisms	of	checkpoint	blockade.	4. Mechanism	 of	 action	 of	 CTLA4	 blockade-in-duced	tumor	rejection.	5. Mechanism	of	action	of	PD-1	blockade-induced	tumor	rejection.	
 
Figure 1: Molecular mechanisms of CTLA4 and PD-1 
attenuation of T-cell activation.	
Mechanism	of	ctla4-mediated	negative	costimula-
tion	CTLA4	 expression	 and	 function	 is	 basically	 linked	with	T-cell	activation.	CTLA4	is	immediately	upregu-lated	 following	 T-cell	 receptor	 (TCR)	 commitment	(signal	1),	with	its	expression	peaking	2	to	3	days	af-ter	activation.	CTLA4	dampens	TCR	signaling	through	competition	with	 the	 costimulatory	molecule	 CD28	for	 the	B7	 ligands	B7-1(CD80)	and	B7-2(CD86),	 for	which	CTLA4	has	higher	avidity	and	affinity	(Figure	:1).	Because	of	both	B7-1	and	B7-2	provide	positive	costimulatory	signals	through	CD28,	competitive	in-hibition	of	both	molecules	by	CTLA4	is	necessary	to	useful.	lt	satisfy	T-cells	activation.	In	addition	to	up-regulation	 of	 CTLA4	 expression	 upon	 T-cell	 activa-tion,	CTLA4	contained	in	intracellular	vesicles	is	rap-idly	trafficked	to	the	immunologic	synapse[3].	The	de-gree	of	recruitment	to	the	immunologic	synpase	cor-relates	 directly	 with	 TCR	 signal	 strength.	 Through	this	mechanism,	CTLA4	attenuates	positive	costimu-lation	by	CD28	and	thus	limits	CD28	downstream	sig-naling,	which	is	primarily	mediated	PI3K	and	AKT[4].	This	fallout	in	robust	regulation	of	TCR	signal	ampli-tude	and	thus,	T-cell	activity.	Because	CTLA4	negative	
costimulation	is	 intrinsically	linked	to	expression	of	B7	 ligands	 and	 CD28-mediated	 positive	 costimula-tion,	CTLA4	primarily	functions	to	regulate	T-cell	ac-tivity	 at	 site	 of	 T-cell	 priming	 (eg;	 secondary	 lym-phoid	 organs).	 In	 addition	 to	 this	 core	 function,	CTLA4	also	attenuates	T-cell	activation	in	peripheral	tissues	 given	 that	 B7	 ligands	 are	 constitutively	 ex-pressed	 to	 varying	 degrees	 by	 antigen-presenting	cells	 (APC)	 but	 can	 also	 expressed	 by	 activated	 T	cells[5].	Because	of	its	vital	role	in	regulating	T-cell	ac-tivation,	negative	costimulation	by	CTLA4	 is	critical	for	tolerance.	The	majority	of	cell-extrinsic	suppres-sive	function	of	CTLA4	is	mediated	through	Regula-tory	 T	 cells	 (Tregs).	 The	 genetic	 loss	 of	 CTLA4	 in	Tregs	in	middle	age.	A	significant	implication	of	this	finding	is	that	Treg	depletion	may	counter	expansion	of	 Treg	 cells	 induced	 by	 CTLA4	 blockade	 and	 thus	lead	to	enhanced	efficacy	of	anti-CTLA4	therapy[6].	
Table 1: List of FDA approved immune checkpoint 
blockade therapy 
Tumor	type	 Therapeutic	agent	
Melanoma	 Ipilimumab	
Melanoma	 Nivolumab	
Melanoma	 Pembrolizumab	
Non–small	cell	lung	cancer	 Nivolumab	
Non–small	cell	lung	cancer	 Pembrolizumab	
Melanoma	(BRAF	wild-
type)	
Ipilimumab	 	nivolumab	
Melanoma	(adjuvant)	 Ipilimumab	
Renal	cell	carcinoma	 Nivolumab	
Hodgkin	lymphoma	 Nivolumab	
Urothelial	carcinoma	 Atezolizumab	
Head	and	neck	squamous	
cell	carcinoma	 Nivolumab	
Head	and	neck	squamous	
cell	carcinoma	 Pembrolizumab	
Melanoma	(any	BRAF	sta-
tus)	
Ipilimumab	 	nivolumab	
Non–small	cell	lung	cancer	 Atezolizumab	
Hodgkin	lymphoma	 Pembrolizumab	
Merkel	cell	carcinoma	 Avelumab	
Urothelial	carcinoma	 Avelumab	
Urothelial	carcinoma	 Durvalumab	
Urothelial	carcinoma	 Nivolumab	
 
Figure 2: Schematic of the molecular mechanisms of 
action of CTLA4 and PD blockade	
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Mechanism	of	pd-1	mediated	attenuation	of	t-cell	
activity	The	key	biological	functions	of	PD-1	are	to	maintain	peripheral	tolerance	and	to	maintain	T-cell	response	within	a	desired	physiologic	range.	Because	the	PD-1/PD-L1	regulatory	system	is	induced	by	immune	re-sponses,	this	forms	a	negative	feedback	loop	to	atten-uate	 local	 T-cell	 response	 and	 reduce	 tissue	 dam-age[7].	 PD-L1	 regulates	 T-cell	 activation	 through	 in-teraction	with	PD-L1	 and	PD-L2	 (Figure:2).	 PD-1	 is	expressed	upon	 activation	 of	 T	 and	B	 lymphocytes.	PD-1	acts	primarily	to	reduce	T-cell	activation	in	the	periphery.	Upon	meeting	with	PD-L1	and	PD-L2,	PD-1	is	through	to	primarily	convey	a	negative	costimu-latory	signal	through	the	tyrosine	phosphatase	SHP2	to	attenuate	T-cell	activation.	The	molecular	mecha-nism	reflects	a	dichotomy	in	modes	of	regulation	uti-lized	by	CTLA4	and	PD-1engagement[8,9].	These	data	indicate	that	 in	contrast	 to	CTLA4	mediated	regula-tion,	PD-1	directly	regulates	TCR	signaling	to	attenu-ate	T-cell	activity.	Recently	 indicates	 that	CD28	 is	a	primary	target	for	PD-1	induced	attenuation	of	T-cell	signaling.	 PD-1	 is	 essential	 for	homeostatic	mainte-nance	of	peripheral	tolerance	as	evidenced	by	the	au-toimmune	pathologies	 that	arise	upon	genetic	dele-tion	of	pdcd1	(encoding	PD-1).	As	an	example	,genetic	loss	of	pdcd1	leads	to	development	of	lupus	like	auto-immune	pathology	in	aged	mice	and	autoimmune	di-lated	cardiomyopathy	in	mice[10].	
Mechanism	 of	 negative	 costimulation	 versus	
mechanisms	of	checkpoint	blockade				Based	on	study	of	how	the	molecule	themselves	act	to	attenuate	T-cell	activity,	it	is	though	that	anti-CTLA4	and	anti-PD-1	primarily	act	at	different	stages	of	the	cancer-immunity	 cycle.	 Obstruction	 of	 PD-1	 is	 suf-ficent	to	improve	the	activity	of	exhasuted	T	cells	in	the	context	of	chronic	viral	infection,	leading	to	viral	clearance.	 Recent	 finding	 demonstrate	 that	 CD28	costimulation	 is	 necessary	 for	 response	 to	 PD-1	blockade	in	the	setting	of	both	viral	infection	and	tu-mor	rejection[11,12].	These	finding	indicates	that	addi-tional	 positive	 costimulation	 is	 required	 for	 thera-peutic	efficacy	despite	prior	activation.	Mechanism	of	action	of	PD-1	and	CTLA4	blockade	and	of	the	normal	biological	 functions	 of	 these	 molecules	 are	 highly	complex	and	clearly	not	fully	understood	[13].	
Mechanism	 of	 action	 of	 ctla4	 blockade-induced	
tumor	rejection	CTLA4	blockade	is	thought	to	encourage	tumor	rejec-tion	 through	a	number	of	distinct	mechanisms.	The	primary	 mechanism	 seems	 to	 be	 through	 direct	blockade	 of	 CTLA4	 competition	 of	 	 B7-1	 and	 B7-2	costimulatory	ligands,	which	allows	for	unrestrained	CD-28	 mediated	 positive	 costimulation[14].	 CTLA4	complex	disclose	that	the	ipilimumab	binding	epitope	overlaps	with	 the	B7	 interaction	domain,	 indicating	that	steric	inhibition	of	B7	interaction	underlies	the	
primary	mechanism	of	action	of	ipilimumab.	It	is	also	possible	that	APCs	within	the	the	tumor	microenviro-ment	may	also	cross	present	tumor	antigens	to	acti-vate	 cognate	 tumor-associated	 antigens[15].	 Promis-ing	 evidence	 suggest	 that	 anti-CTLA4	 does	 not	 im-pose	a	generalized	effect	on	all	T	cells.	CTLA4	block-ade	leads	to	specific	expansion	of	tumor	neoantigen-specific	CD8	T	cells	within	the	tumor	microenviron-ment,	but	secondary	lymphoid	organs[16].		In	addition	to	 these	mechanism	of	CTLA4	blockade-induced	 tu-mor	rejection,	reduction	of	Treg	population	has	also	been	 identified	 as	 a	 mechanism	 of	 action	 of	 anti-CTLA4	 therapy	 in	murine	 tumor	models.	Althrough	other	 prior	 studies	 do	 suggest	 that	 Treg	 depletion	contributes	 to	 the	 mechanism	 of	 action	 of	 anti-CTLA4,	 a	 large	 body	 of	work	 powerfully	 implicates	regulation	of	B7	ligand	interaction	as	a	critical	mech-anism[17].	
Mechanism	of	action	of	pd-1	blockade-induced	tu-
mor	rejection	PD-1	blockade	 is	 capable	 to	 induce	 tumor	 rejection	through	 energy	 of	 CD8	 T	 cells,	 leading	 to	 both	 in-creased	 functional	 activity	 and	 frequency.	Blockade	of	the	PD-1	signaling	axis	avoid	PD-1	mediated	atten-uation	of	proximal	TCR	signaling,	allowing	for	resto-ration	 of	 activity	 of	 exhausted	 CD8	 effectors[18,19].	Current	 evidence	 from	 a	 neoadjuvant	 trial	 of	nivolumab	in	the	context	of	non-small	cell	lung	cancer	support	 the	motion	 that	 anti-PD-1	 therapy	 develop	neoantigen-specific	 T	 cell	 response.	 It	 is	 probable	that	only	specific	T-cell	populations	functionally	me-diate	 response	 to	 checkpoint	 blockade	 therapy[20].	These	 data	 suggest	 that	 PD-1	 blockade	may	 not	 be	enough	to	functionally	restore	Tcells	once	they	reach	a	threshold	 	 level	of	 	exhaustion.	It	remains	unclear	what	 specific	 aspects	 of	 CD4	 help	 are	 functionally	necessary	 for	clinical	response	to	checkpoint	block-ade[21].	
Mechanisms	 of	 resistance	 to	 immunne	
checkpoint	inhibitor	Monoclonal	 antibodies	 targeting	 co-inhibitory	immune	 checkpoints	 (eg;	 PD-1	 and	 CTLA	 4)	 have	demonstrated	clinical	activity	in	several	malignances,	including	melanoma,	non-small	cell	lung	cancer,	renal	cell	 carcinoma	 and	 bladder	 cancer.	 Immune	checkpoint	 inhibitor	 therapy	 has	 been	 particularly	successful	 in	 melanoma,	 for	 which	 approved	treatments	 now	 include	 anti-PD-1	 (nivolumab	 and	pembrolizumab),	 anti-CTLA4	 (ipilimumab),	 and	combination	 anti-PD-1/CTLA-4	 regimens	(nivolumab-ipilimumab).	Long-term	survival	data	for	patients	 with	 melanoma	 treated	 with	 ipilimumab	(anti-CTLA4)	 indicates	 20%	 of	 patients	 show	evidence	 of	 continued	 durable	 disease	 control	 or	response	 5-10	 years	 after	 starting	 therapy.	 The	response	 rate	 for	 melanoma	 patient	 treated	 with	pembrolizumab	(anti-PD-1)	was	33%	at	3years	with	
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70-80%	 of	 patient	 initially	 responding	maintaining	clinical	 response(Figure;	 3).	 Combination	immunotherapy	 or	 dual	 immune	 checkpoint	blockade	 (anti-PD-1	 and	 anti-CTLA-4)	 has	 recently	shown	 spectacular	 response	 rates	 in	 patients	 with	metastatic	melanoma[3].	
Analysis	 of	 clinical	 trial	 data	 can	 identify	 three		
populations	of	patient	1. Peoples	 that	 respond	 initially	 and	 continue	 to	respond	(responder).	2. Peoples	 that	 fail	 to	 ever	 respond	 (innate	resistance).	3. Peoples	 that	 initially	 respond	 but	 eventually	develop	 disease	 progression	 (acquired	resistance).	
 
Figure 3: Schematic representation of mechanism of 
resistance to immune checkpoint inhibitor	Mechanism	of	 innate	and	acquired	resistance	 to	 ICI	(Immune	checkpoint	inhibitor)	therapy	are	not	fully	understood.	 In	 addition,	 few	 immune	 competent	preclinical	models	exist	in	which	tumor	regression	is	induced	by	ICIs,	limiting	the	ability	to	recapitulate	the	diversity	 of	 tumor-immune	 interactions	 in	patients[22]	3	simple	categories		1. Inadequate	generation	of	anti	tumor	T	cells	2. Insufficient	function	of	tumour-specific	T	cells	3. Impaired	formation	of	T-cell	memory	
Inadequate	generation	of	anti-tumour	t-cell	Tumors	can	evolve	to	evade	both	innate	and	adaptive	arms	of	 the	 immune	 system	 there	by	 rendering	 ICI	therapy	ineffective[23,24].	Tumor	intrinsic	mechanisms	of	immune	evasion	include	genetic	and	epigenetic	al-terations	to	influence	neoantigen	formation,	presen-tation,	and/or	processing,	as	well	as	alterations	in	cel-lular	signalling	pathways	that	disrupt	the	action	of	cy-totoxic	T	cells.	Tumor	extrinsic	mechanisms	involve	non-cancerous	stromal	or	immune	cells,	or	other	sys-temic	influences	(e.g.,	host	microbiota)	that	can	act	in	
concert	with	 cancer	 cells	 to	 uphold	 growth	 and	 re-sistance	to	ICI[25].	
Insufficient	function	of	tumor	specific	cell	Successful	 neoantigen	 presentation/cross-presenta-tion	 and	T-cell	 priming,	 the	 expanded	 repertoire	of	anti-tumour	 T	 cells	 faces	 an	 inhospitable	 TME	 that	may	preclude	proper	T-cell	function,	thereby	limiting	the	efficacy	of	ICI	therapy[26].	These	tumour	intrinsic	and	 tumour-extrinsic	 factors	 include	 mutations	 in	key	 effector	 pathways,	 high	 levels	 of	 PD-L1	 	 on	 tu-mour	 cells	 (and	 immune	 cells),	 high	 levels	 of	 alter-nate		immune	checkpoints	or	co-inhibitory	receptors	on	T	cells	(e.g;PD-1,	CTLA-4),	high	levels	of	immune	suppressive	cytokines	or	metabolites,	and	associated	recruitment	of	immune		suppressive		cells	(e.g;mye-loid-derived	 suppressor	 cells	 (MDSCs)	 and	 regula-tory	T	cells	(Tregs)[27].	
Impaired	formation	of	t-cell	memory	The	most	compelling	clinical	evidence	for	the	success	of	ICI	relates	to	the	potential	for	long-term,	durable	clinical	 profit.	 Thus,	 although	 ICI	 may	 temporarily	strengthen	 CTLs	 to	 enhance	 tumour	 control,	 if	formation	 of	 TEM	 cells	 is	 impaired	 then	 clinical	response	could	fade	leading	to	acquired	resistance	or	recurrence	 of	 disease	 following	 discontinuation	 of	therapy.	 Expansion	 of	 intratumoural	 T(EM)	 in	response	 to	PD-1	blockade	has	been	demonstrated,	and	 is	 more	 pronounced	 in	 patients	 responding	 to	therapy,	suggesting	a	key	role	for	TEM	cells	in	anti-PD-1	 action	 and	 clinical	 response.	 The	 cellular	 and	molecular	 mechanisms	 of	 TEM	 expansion	 following	PD-1	blockade	are	not	fully	understood[28,29].	
CONCLUSION	Immune	checkpoint	therapy,	which	target	regulatory	pathways	 in	 T	 cells	 to	 enhance	 antitumor	 immune	responses,	 has	 lead	 to	 important	 clinical	 advances	and	 provide	 a	 new	 weapons	 against	 cancer.	 This	therapy	 has	 elicited	 clinical	 responses	 and,	 in	 a	fraction	 of	 patient,	 long	 term	 remissions	 where	patient	 exhibit	 no	 clinical	 signs	 of	 cancer	 for	many	years.	The	way	forward	for	this	class	of	novel	agents	lies	 in	 our	 ability	 to	 understand	 human	 immune	responses	 in	 tumor	 microenvironment.	 This	 will	provide	valuable	information	regarding	the	dynamic	nature	of	immune	responses	and	regulate	additional	pathways	 that	 will	 need	 to	 be	 targeted	 through	combination	 therapies	 to	 provide	 survival	 benefits	for	greater	numbers	of	patients.	
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